Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single-arm trial to evaluate the efficacy and safety of
Recombinant Coagulation Factor VIII in patients with hemophilia A . Recombinant Coagulation
Factor VIII is prophylactic administrated 25 - 35 IU/kg once every other day or three times
per week which should be continuous for 24 weeks.